Endocrinology, Vol 126, 2153-2163, Copyright © 1990 by Endocrine Society

ARTICLES

Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner

B Staels, A van Tol, G Verhoeven and J Auwerx
Department of Developmental Biology, Katholieke Universiteit, Leuven, Belgium.

The influence of development and estrogen, thyroid hormone, corticosteroid, and fibrate administration on apolipoprotein (apo) A-IV mRNA levels in the liver and intestine and on serum or plasma concentrations of apo A-IV was studied in the rat. Treatment of ovariectomized rats with ethinyl estradiol provoked a dose-dependent decrease in liver apo A-IV mRNA levels, whereas intestinal apo A-IV mRNA did not change. The serum apo A-IV concentration decreased in a dose-dependent manner. Administration of L-T4 increased liver apo A-IV mRNA levels more than 2-fold, while n-propylthiouracil (PTU) decreased these levels more than 4-fold. Intestinal apo A-IV mRNA levels remained constant upon L-T4 treatment, but increased after PTU. Change in thyroid hormone levels caused no significant alteration of plasma apo A- IV levels. Hydrocorticsone increased liver and intestinal apo A-IV mRNA levels 2- and 1.5-fold, respectively, without changing plasma apo A-IV. Liver and intestinal apo A-IV mRNA underwent opposite changes during development. Intestinal apo A-IV mRNA decreased gradually during the period of weaning, while liver apo A-IV mRNA was undetectable before day 20 of life and rose to adult levels thereafter. Both L-T4 and hydrocortisone were able to increase liver apo A-IV mRNA prematurely when rat pups were treated from day 9 on. Hypothyroidism induced by PTU, on the other hand, was able to delay the developmental rise in liver apo A-IV mRNA. The hypolipidemic drug clofibrate reduced liver apo A-IV mRNA more than 10-fold without changing the intestinal levels. Plasma apo A-IV decreased by one third. Ethinyl estradiol, thyroid hormones, and clofibrate regulate apo A-IV mRNA abundance in a tissue- specific manner. Only liver, not intestinal, apo A-IV mRNA levels respond to treatment. Furthermore, opposing changes in liver and intestinal apo A-IV mRNA levels occur during development, and thyroid hormones and glucocorticoids are able to accelerate the developmental changes in liver apo A-IV mRNA.

This article has been cited by other articles:

				A. Soria, C. Bocos, and E. Herrera Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats J. Lipid Res., January 1, 2002; 43(1): 74 - 81. [Abstract] [Full Text] [PDF]

				J. Pacha Development of Intestinal Transport Function in Mammals Physiol Rev, October 1, 2000; 80(4): 1633 - 1667. [Abstract] [Full Text] [PDF]

				E. Raspé, L. Madsen, A-M. Lefebvre, I. Leitersdorf, L. Gelman, J. Peinado-Onsurbe, J. Dallongeville, J-C. Fruchart, R. Berge, and B. Staels Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPAR{alpha} activation J. Lipid Res., November 1, 1999; 40(11): 2099 - 2110. [Abstract] [Full Text]

				P. Gervois, I. P. Torra, G. Chinetti, T. Grötzinger, G. Dubois, J.-C. Fruchart, J. Fruchart-Najib, E. Leitersdorf, and B. Staels A Truncated Human Peroxisome Proliferator-Activated Receptor {alpha} Splice Variant with Dominant Negative Activity Mol. Endocrinol., September 1, 1999; 13(9): 1535 - 1549. [Abstract] [Full Text]

				N. Hennuyer, P. Poulain, L. Madsen, R. K. Berge, L.-M. Houdebine, D. Branellec, J.-C. Fruchart, C. Fievet, N. Duverger, and B. Staels Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism Occur Independently of Any Peroxisome Proliferative Response Circulation, May 11, 1999; 99(18): 2445 - 2451. [Abstract] [Full Text] [PDF]

				P. Gervois, S. Chopin-Delannoy, A. Fadel, G. Dubois, V. Kosykh, J.-C. Fruchart, J. Najïb, V. Laudet, and B. Staels Fibrates Increase Human REV-ERB{alpha} Expression in Liver via a Novel Peroxisome Proliferator-Activated Receptor Response Element Mol. Endocrinol., March 1, 1999; 13(3): 400 - 409. [Abstract] [Full Text]

				N. Vu-Dac, S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J.-C. Fruchart, V. Laudet, and B. Staels The Nuclear Receptors Peroxisome Proliferator-activated Receptor alpha  and Rev-erbalpha Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates J. Biol. Chem., October 2, 1998; 273(40): 25713 - 25720. [Abstract] [Full Text] [PDF]

				N. Vu-Dac, P. Gervois, T. Grotzinger, P. De Vos, K. Schoonjans, J.-C. Fruchart, J. Auwerx, J. Mariani, A. Tedgui, and B. Staels Transcriptional Regulation of Apolipoprotein A-I Gene Expression by the Nuclear Receptor RORalpha J. Biol. Chem., September 5, 1997; 272(36): 22401 - 22404. [Abstract] [Full Text] [PDF]

				A.-M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J.-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels Regulation of Lipoprotein Metabolism by Thiazolidinediones Occurs through a Distinct but Complementary Mechanism Relative to Fibrates Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1756 - 1764. [Abstract] [Full Text]

				T. J. Kalogeris, M.-D. Rodriguez, and P. Tso Control of Synthesis and Secretion of Intestinal Apolipoprotein A-IV by Lipid J. Nutr., March 1, 1997; 127(3): 537 - 537. [Abstract] [Full Text]